Cardiovascular Disease

Patients with obesity and hypertension need to be aggressively treated in order to decrease their risk of cardiovascular complications, says Dr Jonathan Parker, President of the Alabama Obesity Society.

Dr Chiadi Ndumele explains the need for the more comprehensive and also nuanced qualitative approach to estimating long-term CVD risk.

AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.

Your daily dose of the clinical news you may have missed.

A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.

A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Etripamil 70 mg nasal spray restored heart rate within 30 minutes in approximately 60% of PSVT episodes, report authors of new study.

Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.

The biosimilar to the GLP-1 mimetic Victoza proved noninferior for reduction of HbA1c and had similar positive effects on body weight, lipids, and blood pressure.

The AZALEA-TIMI 71 trial was stopped early due to an "overwhelming reduction" in a composite endpoint of major bleeding events compared to rivaroxaban standard of care.

Your daily dose of the clinical news you may have missed.

Your daily dose of clinical news you may have missed.

Persons with HTN while in a supine position had a higher risk for CVD even if they did not have HTN while seated, according to new research presented at Hypertension 2023.

Your daily dose of clinical news you may have missed.

Get a quick look at the US worst states for health care ranked using a composite score that included measures of cost, access, and outcomes.

Atrial fibrillation prevalence is rising across socioeconomic strata globally, the new analysis finds, with effects of BMI, ETOH, and sedentary behavior shifting as key drivers.

The best states for health care were ranked using a composite score that included measures of cost, access, and outcomes. So, which state retains the most residents?

Your daily dose of clinical news you may have missed.

ESC 2023: New data showed an aspirin-free strategy after PCI did not reduce major bleeding event risk vs DAPT, while omission of aspirin proved noninferior for CV events in high-risk patients.

ESC 2023: Early initiation of dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in patients hospitalized with ADHF.

A daily dose of clinical news on Patient Care you may have missed.

A daily dose of clinical news on Patient Care you may have missed.

In an analysis of participant data from health surveys, less than half of eligible persons in the overall pooled sample were taking aspirin for secondary prevention of CVD.

More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.

Dr Alina Elperin details which medications primary care clinicians should be prepared to prescribe patients with obesity to help prevent cardiovascular disease, here.

Excess CVD mortality among Black vs White adults was diminished after control for behavior/metabolic factors and negligible after adjustments for SDOH, a new study reveals.

A daily dose of clinical news on Patient Care you may have missed.

A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.